MariMed Announces First Quarter 2026 Earnings Date

Rhea-AI Summary

MariMed (CSE: MRMD; OTCQB: MRMD) will report first quarter 2026 financial results on May 13, 2026 after market close. Management will host a conference call on May 14, 2026 at 8:00 a.m. EDT with a live webcast and on‑demand playback on the company investor relations site.

News Market Reaction – MRMD

-2.78%

-2.78% Session close to close

In the Apr 16 session, MRMD declined 2.78%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NORWOOD, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading cannabis consumer packaged goods company and retailer, announced today it will report its first quarter 2026 financial results on May 13, 2026 after the markets close. Management will host a conference call on May 14, 2026 at 8:00 a.m. EDT to discuss financial results.

A webcast will be available and can be accessed via MariMed’s Investor Relations website at MariMed Q1 2026 Earnings Webcast. A playback of the call will also be made available on MariMed’s Investor Relations website.

About MariMed
MariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including Betty's Eddies™, Bubby’s Baked™, InHouse™, Nature’s Heritage™, and Vibations™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. The Company is also recognized for delivering exceptional customer service at our 13 Thrive Dispensary retail locations across five states. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit www.marimedinc.com.

Company Contact:
Howard Schacter
Chief Communications Officer 
Email: hschacter@marimedinc.com
Phone: (781) 277-0007

FAQ

When will MariMed (MRMD) report Q1 2026 earnings and when is the conference call?

MariMed will report Q1 2026 results on May 13, 2026 after market close. According to the company, a conference call is scheduled for May 14, 2026 at 8:00 a.m. EDT to discuss the results and take questions.

How can investors access the MariMed (MRMD) Q1 2026 earnings webcast and replay?

Investors can access the live webcast and playback via MariMed's investor relations website. According to the company, the webcast will stream at the scheduled call time and a replay will be posted on the same investor site afterward.

Who will present on the MariMed (MRMD) Q1 2026 earnings conference call?

According to the company, MariMed management will host the conference call to review first quarter 2026 financial results. The call will cover reported results and management commentary followed by a Q&A session for investors and analysts.

What time zone is the MariMed (MRMD) earnings call scheduled in for May 14, 2026?

The MariMed earnings call is scheduled for 8:00 a.m. EDT on May 14, 2026. According to the company, investors should convert to local time zones to join the live webcast or call promptly at the start time.

Will MariMed (MRMD) provide a replay of the Q1 2026 earnings call if I miss the live event?

Yes. According to the company, a playback of the conference call will be made available on MariMed's investor relations website after the live webcast, enabling investors to review the presentation and Q&A at their convenience.

What topics will MariMed (MRMD) likely cover on the Q1 2026 earnings call?

The call will review first quarter 2026 financial results and offer management commentary on operations and outlook. According to the company, management will discuss reported results and answer investor and analyst questions during the session.